Significance of urinary liver-fatty acid-binding protein in cardiac catheterization in patients with coronary artery disease

Internal Medicine

Volumn 48, Issue 19, 2009, Pages 1731-1737

  Fukuda, Yusuke ^a   Miura, Shin Ichiro ^a   Zhang, Bo ^a   Iwata, Atsushi ^a   Kawamura, Akira ^a   Nishikawa, Hiroaki ^a   Shirai, Kazuyuki ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute coronary syndrome; Percutaneous coronary intervention; Stable angina; Urinary liver fatty acid binding protein

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; FATTY ACID BINDING PROTEIN; GLYCERYL TRINITRATE; HEPARIN; LIVER PROTEIN; N ACETYL BETA GLUCOSAMINIDASE; TICLOPIDINE; TROPONIN T; UNCLASSIFIED DRUG; URIC ACID; URINARY LIVER FATTY ACID BINDING PROTEIN; VESICULAR GLUTAMATE TRANSPORTER;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; CLINICAL ARTICLE; COLORIMETRY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; FEMALE; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HUMAN; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; STABLE ANGINA PECTORIS; URINALYSIS;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CREATININE; FATTY ACID-BINDING PROTEINS; FEMALE; GLOMERULAR FILTRATION RATE; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 70450189268     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2410     Document Type: Article

References (22)

1. Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins: their function and physiological significance. Prog Lipid Res 35: 243-282, 1996.
2. Glatz JF, van Bilsen M, Paulussen RJ, et al. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta 961: 148-152, 1988.
3. Ramsammy LS, Josepovitz C, Lane BP, et al. Polyaspartic acid protects against gentamicin nephrotoxicity in the rat. J Pharmacol Exp Ther 250: 149-153, 1989. (Pubitemid 19194984)
4. Kamijo A, Sugaya T, Hikawa A, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 165: 1243-1255, 2004. (Pubitemid 39297730)
5. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134: 629-636, 2001.
6. Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.
7. Berton G, Citro T, Palmieri R, et al. Albumin excretion rate increases during acute myocardial infarction and strongly predicts early mortality. Circulation 96: 3338-3345, 1997. (Pubitemid 27513403)
8. Matthys E, Patel Y, Kreisberg J, et al. Lipid alterations induced by renal ischemia: pathogenic factor in membrane damage. Kidney Int 26: 153-161, 1984. (Pubitemid 14017053)
9. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 343: 155-158, 1994. (Pubitemid 124000837)
10. Kurien VA, Oliver MF. Serum-free-fatty-acids after acute myocardial infarction and cerebral vascular occlusion. Lancet 2: 122-127, 1966.
11. Cantor WJ, Kim HH, Jolly S, et al. B-type natriuretic peptide and serum unbound free fatty acid levels after contemporary percutaneous coronary intervention. J Invasive Cardiol 20: 186-188, 2008.
12. Richieri GV, Ogata RT, Kleinfeld AM. A fluorescently labeled intestinal fatty acid binding protein. Interactions with fatty acids and its use in monitoring free fatty acids. J Biol Chem 267: 23495-23501, 1992.
13. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med 332: 647-655, 1995.
14. Kleinfeld AM, Prothro D, Brown DL, et al. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol 78: 1350-1354, 1996.
15. Azzazy HM, Pelsers MM, Christenson RH. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem 52: 19-29, 2006.
16. Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis 47: 439-444, 2006. (Pubitemid 43255177)
17. Nakamura T, Sugaya T, Kawagoe Y, et al. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. Am J Med Sci 330: 161-165, 2005. (Pubitemid 41512989)
18. Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 333: 321-326, 2007. (Pubitemid 46945471)
19. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 28: 2728-2732, 2005. (Pubitemid 43951167)
20. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev 22: 385-389, 2006. (Pubitemid 44446434)
21. Kato K, Sato N, Yamamoto T, Iwasaki YK, Tanaka K, Mizuno K. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circ J 72: 1499-1505, 2008.
22. Sasaki H, Kamijo-Ikemori A, Sugaya T, et al. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract 112: c148-c156, 2009.